1. Search Result
Search Result
Results for "

PLGA-COOH (MW 80000) (LA/GA 50:50)

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2247A

    poly(lactic-co-glycolic acid) (75:25)

    Biochemical Assay Reagents Others
    PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .
    <em>PLGA</em> (75:25)
  • HY-145396

    Others Cancer
    PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .
    <em>PLGA</em>-PEG-NH2
  • HY-158255

    Biochemical Assay Reagents Others
    mPEG-PLGA (2000-80000) (LA/GA 50:50) is a copolymer, which consists of hydrophilic mPEG and biodegradable PLGA (molar ratio is 50:50) with a molecular weight of 2000 (mPEG) + 80000 (PLGA). mPEG-PLGA (2000-80000) (LA/GA 50:50) forms nanoparticles or microparticles, which is stable in aqueous solution at different pH values and elevated temperatures as well as in serum. mPEG-PLGA (2000-80000) (LA/GA 50:50) is utilized as carrier material in drug delivery systems .
    mPEG-<em>PLGA</em> (2000-<em>80000</em>) (LA/GA 50:50)
  • HY-156829

    Others Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 1:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    <em>PLGA</em>-PEG-<em>PLGA</em> (1500-1500-1500) (LA/GA 1:1)
  • HY-156829A

    Others Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 15:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    <em>PLGA</em>-PEG-<em>PLGA</em> (1500-1500-1500) (LA/GA 15:1)
  • HY-158089

    Biochemical Assay Reagents Others
    PLGA-COOH (MW 80000) (LA/GA 50:50) is a copolymer, which consist of lactic acid (LA)-glycolic acid (GA) with a molar ratio of 50:50, and a carboxyl terminal groups. PLGA-COOH (MW 80000) (LA/GA 50:50) is utilized in drug delivery system for its biocompatibility and biodegradability .
    <em>PLGA</em>-<em>COOH</em> (MW <em>80000</em>) (LA/GA 50:50)
  • HY-D0153

    Fluorescent Dye Cancer
    Tetramethylrhodamine-5-isothiocyanate is a potent fluorescent dye. Tetramethylrhodamine-5-isothiocyanate can be used for label PG-M3 antibody for rapid diagnosis of acute promyelocytic leukemia (APL). Tetramethylrhodamine-5-isothiocyanate can be used as probe to quantify in vivo the biodistribution of PLGA (poly(lactic-co-glycolic) acid) and PLGA/chitosan nanoparticles .
    Tetramethylrhodamine-5-isothiocyanate
  • HY-148775

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    <em>PLGA</em>-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
  • HY-148775B

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    <em>PLGA</em>-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)
  • HY-148776

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .
    <em>PLGA</em>-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)
  • HY-B2247
    PLGA (50:50)
    10+ Cited Publications

    poly(lactic-co-glycolic acid) (50:50)

    Biochemical Assay Reagents Others
    PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.
    <em>PLGA</em> (50:50)
  • HY-W409806

    Liposome Inflammation/Immunology
    Cholesterylamine is a cationic lipid. Cholesterylamine can be added to the PLGA to prepare PLGA particle having surface charge. Cholesterylamine can be used for drug delivery. Cholesterylamine can be used for autoimmune diseases and allergy research .
    Cholesterylamine
  • HY-P1170

    Ac-L-Tyr-Gly-Gly-L-Phe-D-Leu-COOH

    Opioid Receptor Neurological Disease
    N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.
    N-terminally acetylated Leu-enkephalin
  • HY-P1985A

    Notch Cardiovascular Disease Cancer
    Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .
    Notch 1 TFA
  • HY-W010713

    Fimaporfin free base

    Others Cancer
    Meso-tetraphenylchlorin (TPCS2a) is a photosensitizer with poor water solubility, which limits its use in the blood circulation. However, TPCS2a@NPs nanoparticles can be prepared based on polylactic-co-polyethylene glycol acid (PLGA) polymer core loaded with TPCS2. Such nanoparticles can be coated with mesenchymal stem cell-derived plasma membranes (mMSCs) to form mMSC-TPCS2a@NPs, which prolongs blood circulation time and improves tumor targeting ability. Compared with uncoated TPCS2a@NPs, mMSC-TPCS2a@NPs can reduce macrophage uptake by 54% to 70% under different conditions. Both nanoparticle forms are effectively accumulated in MCF7 and MDA-MB-231 breast cancer cells, while uptake in normal breast epithelial cells MCF10A is significantly lower .
    Meso-tetraphenylchlorin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: